Entzündungssignal RANTES / CCL5 aus dem Kieferknochen

Summary

Hintergrund: Diese Studie behandelt die Frage, ob allgemeine und weit verbreitete zahnärztliche Eingriffe, wie Zahnextraktionen und operative Entfernung von Weisheitszähnen, zu chronischer Kieferknochenentzündung führen. Eine mangelhafte Wundheilung im Kieferknochen kann über Entzündungsmediatoren eine versteckte Ursache chronischer Erkrankungen sein.

Materialien und Methoden: Mittels Mutliplexanalyse untersuchen wir fettig-degenerativ osteonekrotisch / osteolytisch veränderten Kieferknochen (FDOK) in zwei Gruppen auf sieben Zytokine: 16 FDOK-Präparate postoperativ in Bereichen der retromolaren Weisheitszahngebiete und 19 Präparate von gesundem Kieferknochen.

Ergebnisse: Alle FDOK-Proben zeigen RANTES / CCL5 (R / C) und den Fibroblastenwachstumsfaktor (FGF)-2 als einzige stark überexprimierte Botenstoffe. Die FDOK-Proben zeigen im Mittel einen 30-fachen Überschuss von R / C und einen 20-fachen Überschuss von FGF-2 im Vergleich zu gesunden Kontrollgruppen.

Schlussfolgerungen: Da R / C in der Literatur als wichtiger Treiber von entzündlichen Erkrankungen diskutiert wird und onkogene Wirkung haben kann, verfolgen wir die Hypothese, dass FDOK infolge mangelhafter oder unvollständiger Wundheilung im Kieferknochen eine Quelle hyperaktivierter Signalwege ist. Dabei wirkt das FDOK-Areal als unentdeckter Herd einer „stillen Entzündung“. Aufgrund der R / C-Beteiligungen bei vielen Immunerkrankungen kann die chirurgische Beseitigung einer FDOK potenzielle Entwicklungen von entzündlich systemischen Erkrankungen positiv beeinflussen.

Keywords

Chronische Entzündung - fettig degenerativer osteolytischer Kieferknochen - hyperaktivierte Signalwege - RANTES/CCL5 - rheumatische Arthritis - Brustkrebs

• Literatur

• 1 Townsend MJ, McKenzie AN. Unravelling the net? Cytokines and diseases. J Cell Sci 2000; 113 (Pt 20) 3549-3550
• 2 Imbeau J. Introduction to through-transmission alveolar ultrasonography (TAU) in dental medicine. Cranio 2005; 23 (02) 100-112
• 3 Ratner EJ, Langer B, Evins ML. Alveolar cavitational osteopathosis: Manifestations of an infectious process and its implication in the causation of chronic pain. J Periodontol 1986; 57: 593
• 4 Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 1992; 326: 1473
• 5 Ono K. editor. Symposium: Recent advances in avascular osteonecrosis. Clin Orthop 1992; 277: 2
• 6 Graff-Radford SB, Simmons M, Fox L. et al.. Are bony cavities exclusively associated with atypical facial pain and trigeminal neuralgia?. Proceedings of Annual Meeting, Western USA Pain Society, Santa Fe, New Mexico; May 1988
• 7 Bouquot JE, Roberts AM, Person P. et al. NICO (neuralgia-inducing cavitational osteonecrosis): Osteomyelitis in 224 jawbone samples from patients with facial neuralgias. Oral Surg Oral Med Oral Pathol 1992; 73: 307
• 8 Vieira AE, Repeke CE, Ferreira Junior SdB. et al. Intramembranous bone healing process subsequent to tooth extraction in mice: micro-computed tomography, histomorphometric and molecular characterization. PLoS ONE 2015; 10 (05) e0128021 doi:10.1371/journal.pone.0128021
• 9 Lechner J, von Baehr V. RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?. Int J Gen Med 2013; 6: 277-290
• 10 Kwon OJ, Jose PJ, Robbins RA. et al. Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. Am J Respir Cell Mol Biol 1995; 12 (05) 488-496
• 11 Panettieri Jr RA. Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 2002; 26 (04) 465-474
• 12 Azenshtein E. et al. The CC chemokine RANTES in breast carcinoma progression – regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62: 1093
• 13 Rathanaswami P. et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chemistr 1993; 268 (08) 5834-5839
• 14 Volin MV. et al. RANTES expression and contribution to monocyte chemotaxis in arthritis. Clin Immunol Immunopathol 1998; 89 (01) 44-53
• 15 Alaaeddine N, Olee T, Hashimoto S. et al. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum 2001; 44: 1633-1643
• 16 Arima K, Nasu K, Narahara H. et al. Effects of lipopolysaccharide and cytokines on production of RANTES by cultured human endometrial stromal cells. Mol Hum Reprod 2000; 6 (03) 246-251
• 17 Wolf G, Aberle S, Thaiss F. et al. TNF-a induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int 1993; 44: 795-804
• 18 Briones MA. et al. Expression of chemokine by human coronary-artery and umbilical-vein endothelial cells and its regulation by inflammatory cytokines. Coron Artery Dis 2001; 12 (03) 179-186
• 19 Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. Curr Opin Pharmacol 2012; 12 (01) 55-61
• 20 Glück T, Opal SM. Advances in sepsis therapy. Drugs 2004; 64: 837-859
• 21 Straub RH. Hrsg. Lehrbuch der klinischen Pathophysiologie komplexer chronischer Erkrankungen. Band 2: Spezielle Pathophysiologie Göttingen: Vandenhoeck & Ruprecht; 2007
• 22 Ramesh G, MacLean A, Philipp M. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm 2013. doi: 10.1155/2013/480739
• 23 Levy JA. The unexpected pleiotropic activities of RANTES. J Immunol 182 (07) 3945-3946
• 24 von Luettichau I, Nelson PJ, Pattison JM. et al. RANTES chemokine expression in diseased and normal human tissues. Cytokine 1996; 8: 89-98
• 25 Rathanaswami P, Hachicha M, Sadick M. et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES genes by inflammatory cytokines. J Biol Chem 1993; 268 (08) 5834-5839
• 26 Hirano F, Kobayashi A, Hirano Y. et al. Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. Ann Rheum Dis 2002; 61 (09) 834-837
• 27 Robinson E, Keystone EC, Schall TJ. et al. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1β production by synovial T cells. Clin Exp Immunol 1995; 101 (03) 398-407
• 28 Chicheportiche Y, Chicheportiche R, Sizing I. et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002; 4 (02) 126-133
• 29 Wang CR, Guo HR, Liu MF. RANTES promoter polymorphism as a genetic risk factor for rheumatoid arthritis in the Chinese. Clin Exp Rheumatol 2005; 23 (03) 379-384
• 30 Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267: 271-285
• 31 Wigler N. Breast carcinoma: a report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease. Isr Med Assoc J 2002; 4 (Suppl. 11) 940-943
• 32 Niwa Y, Akamatsu H, Niwa H. et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001; 7 (02) 285-289
• 33 Lechner J. Validation of dental X-ray by cytokine RANTES – comparison of X-ray findings with cytokine overexpression in jawbone. Clin Cosmet Investig Dent 2014; 6: 71-79
• 34 Bouquot JE, Margolis M, Shankland W. et al. Through-transmission alveolar ultrasonography (TAU): New technology for evaluation of medullary diseases. Correlation with histopathology of 285 scanned jaw sites. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 210
• 35 Bouquot J, Martin W, Wrobleski G. Computer-based thru-transmission sonography (CTS) imaging of ischemic osteonecrosis of the jaws – a preliminary investigation of 6 cadaver jaws and 15 pain patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 550
• 36 Boas EP, Michelson N, Doane JC. The challenge of chronic diseases. Am J Nurs 1930; 30: 372-373